Stock listing
A4098S Stock Price, News, Filings & Events — Palisade Bio, Inc.
Selected listing: A4098S · LS · EUR · DE
This page tracks Palisade Bio, Inc.'s A4098S:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A4098S:LS. A4098S:LS is the stock-level entry point for investors researching Palisade Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Palisade Bio, Inc. (Ticker: PALI) is a public company based in the United States, with a market capitalization of approximately $342 million. The company focuses on developing innovative therapies to improve patient outcomes. Palisade Bio is committed to advancing its pipeline of products aimed at addressing unmet medical needs.
- Ticker
- A4098S:LS
- Asset type
- Stock
- Market cap
- $359.0M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Palisade Bio, Inc. A4098S:LS stock context
This page tracks Palisade Bio, Inc.'s A4098S:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A4098S:LS. A4098S:LS is the stock-level entry point for investors researching Palisade Bio, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Palisade Bio, Inc. (Ticker: PALI) is a public company based in the United States, with a market capitalization of approximately $342 million. The company focuses on developing innovative therapies to improve patient outcomes. Palisade Bio is committed to advancing its pipeline of products aimed at addressing unmet medical needs.
Latest news from Palisade Bio, Inc.
Palisade Bio to Participate in Upcoming Investor Conferences
September 3, 2026
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
August 10, 2026
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
July 10, 2026
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
June 29, 2026
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
June 11, 2026
Research Palisade Bio, Inc.
Palisade Bio, Inc. investor report
Review AI stock analysis and investor report context for A4098S:LS.
Palisade Bio, Inc. company profile
View the public company page for Palisade Bio, Inc. on 6ix.
Palisade Bio, Inc. news
Read company news and market updates connected to Palisade Bio, Inc..
Palisade Bio, Inc. investor events
Find investor webinars, events, and replay context for Palisade Bio, Inc..
Alternate listings
PALI:NASDAQ
US · USD
Alternate listing for Palisade Bio, Inc.; the primary context on this page is A4098S:LS.
PALI:BOATS
US · USD
Alternate listing for Palisade Bio, Inc.; the primary context on this page is A4098S:LS.
7NS0:GETTEX
DE · EUR
Alternate listing for Palisade Bio, Inc.; the primary context on this page is A4098S:LS.
7NS0:FWB
DE · EUR
Alternate listing for Palisade Bio, Inc.; the primary context on this page is A4098S:LS.
7NS0:MUN
DE · EUR
Alternate listing for Palisade Bio, Inc.; the primary context on this page is A4098S:LS.